Related Experiment Video
Updated: Nov 1, 2025
07:00
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
9.7K
How glucagon-like peptide 1 receptor agonists work
Christine Rode Andreasen1,2, Andreas Andersen1,2, Filip Krag Knop1,2,3,4
1Steno Diabetes Center Copenhagen, Gentofte, Denmark.
Endocrine Connections
|June 17, 2021
Summary
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are effective for type 2 diabetes, offering glucose control, weight loss, and cardio-renal protection. Their diverse mechanisms and potential for other diseases are explored.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly central to type 2 diabetes (T2D) management.
- Beyond glycemic control, GLP-1RAs offer weight reduction and significant cardio-renal protective benefits.
- Current guidelines recommend GLP-1RAs for overweight T2D patients and those with cardiovascular disease.
Purpose of the Study:
- To review approved GLP-1RAs, their clinical effects, and mechanisms of action.
- To explore the potential of GLP-1RAs for non-T2D indications like non-alcoholic steatohepatitis and neurodegenerative disorders.
- To discuss emerging data on combination therapies involving GLP-1RAs.
Main Methods:
- Comprehensive literature review of approved GLP-1RAs.
- Analysis of pharmacokinetic profiles and clinical outcomes.
- Exploration of pleiotropic effects and potential new indications.
Main Results:
- GLP-1RAs demonstrate varied efficacy in glycemic control, weight reduction, and cardio-renal protection.
- Understanding their multifaceted actions is key to optimizing clinical use.
- Emerging evidence suggests potential applications beyond T2D.
Conclusions:
- GLP-1RAs are vital in T2D treatment, with evolving roles and expanding therapeutic potential.
- Further research into their mechanisms and combination therapies may unlock new treatment paradigms.
- GLP-1RAs show promise for conditions such as non-alcoholic steatohepatitis and neurodegenerative diseases.
More Related Videos
Related Concept Videos
01:24Glucagon-like Receptor Agonists
507
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
507
01:06Oral Hypoglycemic Agents: Glinides
338
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
338
01:28Insulin: The Receptor and Signaling Pathways
1.8K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.8K
01:09GPCRs Regulate Adenylyl Cylase Activity
6.2K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.2K
01:16Hormones Regulating Blood Glucose
5.3K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
5.3K
01:23Dipeptidyl Peptidase 4 Inhibitors
313
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
313